Nuclea Biotechnologies, based in Pittsfield, MA, is partnering with the Boston Medical Center to research and develop biomarkers for patients with breast and prostate cancers. Under the partnership, Nuclea will pay Boston Medical Center about $1.4 million over the next three years to support the research. Nuclea will have the right to commercialize discoveries relating to biomarker development and biomarker arrays.
Mass High Tech reports that B. Nicolas Bloch of the Boston Medical Center's department of radiology will serve as principal investigator. Patrick Muraca, Nuclea's president and CEO, said in a statement that the partnership will lead to new biomarker discoveries and allow the company to grow its clinical trials. Nuclea currently commercializes 11 diagnostic tests, including those for for colon, breast, leukemia, lung and prostate cancer.
Nuclea says its Tissue MicroArray technology allows raw gene sequence information to be profiled on thousands of tissue samples, identifying the role of these genes in specific human disease. The results are then linked to data on known gene markers in Nuclea's database.
- read the story in Mass High Tech